@csgarrix
Account based inUnited States
About this account
- Account based in
- United States
- Connected via
- United States App Store
Account-level information from X, not a live location or the device used for a specific post.
Assistant Professor Mass General @MGHCSB @MGHPathology and Harvard Med @harvardmed specializing in Immuno-Oncology with a focus on Dendritic Cells.
Boston, MA
Joined November 2013
- Tweets1.6K
- Following1.1K
- Followers858
- Likes5.7K
Christopher Garris retweeted
🔥Hot off the press: A new study in @Cancer_Cell from Dr. Weichselbaum (@rweichselbaum) and colleagues show how high-dose radiation increases TET2 expression, activating immunosuppressive MDSCs to drive tumor progression. @UChicagoRadonc @UChicagoMed
ow.ly/zj6J50ZOR6z
Fantastic study. With the recent resurgence in cancer vaccines, we should also consider that communication with cDC1 could be critical for response. Ken’s recent paper even shows potential long-term deficiencies in CD8 T cells activated through dressed cDC2. cDC1 remains king. 👑
1/15 academic.oup.com/jimmunol/ar… New study from a collaboration between the Gubin lab and @swatowic Watowich lab and led by Josué Pineda and Tomoyuki Minowa. Long read, I know. Type 1 conventional dendritic cells (DC1s) play a central role in coordinating antitumor immunity, yet
Christopher Garris retweeted
1/15 academic.oup.com/jimmunol/ar… New study from a collaboration between the Gubin lab and @swatowic Watowich lab and led by Josué Pineda and Tomoyuki Minowa. Long read, I know. Type 1 conventional dendritic cells (DC1s) play a central role in coordinating antitumor immunity, yet
Great summary of a fun collaborative project with @CarvalhoFilipeL @VanAllenLab and others! @DanaFarber_GU
Christopher Garris retweeted
With cancer vaccines now being discovered with AI ($MRNA), it seems that the US government might actually grow its way out of its budget deficit.
It feels like we're in the early innings of the healthcare system becoming unburdened by many terminal illnesses.
Christopher Garris retweeted
Huge congrats to $MRK and $MRNA! The entire personalized cancer vaccine platform is now de-risked, many more cancer types to come
Now it's interesting to see what that means for $PSNL, the sole company helping $MRK and $MRNA to sequence these tumors and design these neoantigrn vaccines
🚨🚨🚨BREAKING CANCER NEWS! 🚨🚨🚨
Merck $MRK and Moderna $MRNA personalized mRNA cancer vaccine slowed the return of melanoma and its spread to other parts of the body in a Ph3 clinical trial.
No data disclosed yet, but the study was stopped for positive results at the first interim analysis.
Magnitude of benefit TBD, but this is a potentially huge breakthrough for cancer patients and the use of mRNA to treat cancer.
Read STAT's story from @matthewherper and @angRchen
statnews.com/2026/08/19/mrna…
Christopher Garris retweeted
🚨🚨🚨BREAKING CANCER NEWS! 🚨🚨🚨
Merck $MRK and Moderna $MRNA personalized mRNA cancer vaccine slowed the return of melanoma and its spread to other parts of the body in a Ph3 clinical trial.
No data disclosed yet, but the study was stopped for positive results at the first interim analysis.
Magnitude of benefit TBD, but this is a potentially huge breakthrough for cancer patients and the use of mRNA to treat cancer.
Read STAT's story from @matthewherper and @angRchen
statnews.com/2026/08/19/mrna…
Christopher Garris retweeted
1/ Why have anti-GITR agonists, despite strong preclinical activity, shown limited clinical success?
Our new study in @NatureCancer points to Fc receptor pathways as a key missing piece.
Led by the amazing @AvYahel, Natasha Barth
nature.com/articles/s43018-0…
Christopher Garris retweeted
Online now: Driving tumor-associated macrophages to a CXCL9Hi/SPP1Low phenotype eliminates pancreatic cancer dlvr.it/TTplgV
Christopher Garris retweeted
Thank you to @CBSNews for highlighting our #research!
For many patients with muscle-invasive #BladderCancer, the standard of care is neoadjuvant systemic therapy followed by curative surgery to remove the bladder. For selected patients, bladder-preserving approaches are already an option, and the field is working to expand who can safely benefit.
Our #research at @WeillCornell @nyphospital combines patient-derived cancer organoids with AI to create “bio-digital avatars” of each patient's cancer.
This is team science, bringing together clinicians, laboratory scientists, computational biologists and mathematicians. We envision that these technologies could eventually help predict each patient’s response to treatment. Rigorous prospective validation will be essential before they can guide routine clinical care. @Cornell @WCMGUcancer @WCMEnglanderIPM @WCM_MeyerCancer @BladderCancerUS #FaltasLab
Sigh… another “finalist” level proposal waitlisted again and likely won’t be funded. This keeps on happening and oddly, I’d prefer the hard reject as opposed to the repeated near misses; that way I wouldn’t keep wasting time and have more reason to course correct.
Christopher Garris retweeted
Cancer immunotherapy targeting murine myeloid cells requires endosomal pattern recognition @NatureComms @karolinskainst
nature.com/articles/s41467-0…
Christopher Garris retweeted
Tumors are reprogrammed in vivo into a universal vaccine, triggering a robust immune response to eradicate cancer @ScienceAdvances 🇨🇳
science.org/doi/10.1126/scia…
Christopher Garris retweeted
Review @JExpMed @BhardwajLab
Leveraging cDC1 biology and function for enhanced immunotherapy
rupress.org/jem/article/223/…
Christopher Garris retweeted
Excited to share out latest work, out this week in @NatureGenet . In this study, we using CRISPR screens to explore how sensing inflammatory cytokines exposes new tumor-intrinsic dependencies.
@broadinstitute @MGBResearchNews
nature.com/articles/s41588-0…
Christopher Garris retweeted
Important Request for Information (RFI) from @NIH
“Proposal to Cap the Number of Simultaneous Research Project Grants per Principal Investigator to Support More Researchers and Maximize Scientific Productivity and Innovation”
grants.nih.gov/grants/guide/…
Some suggested caps & impact:
Christopher Garris retweeted
Here’s our latest, we explored tumor B-cell infiltration in advanced urothelial carcinoma. Exciting collaboration with @OncoBellmunt Congrats to leading authors @KonradStawiski @PereraBel
#BladderCancer #Bcells #TLS #MIBC
Christopher Garris retweeted
Another major advance vs cancer! @ASCO #ASCO26
Personalized neoantigen mRNA vaccine 5 year follow-up vs metastatic melanoma reduced recurrence and death by 49% (on top of Keytruda)
ascopubs.org/doi/10.1200/JCO…
Christopher Garris retweeted
$3.1B! Congrats @brian_armstrong
Epigenetic restoration is sure heating up
Exclusive: A longevity biotech co-founded by Coinbase’s CEO more than tripled in value to $3.1 billion—before its drugs begin human testing. on.wsj.com/4fmQi8m
